Schering Goes After Impax Over Vytorin ANDA

Law360, New York (August 23, 2010, 4:54 PM EDT) -- Schering Corp. and MSP Singapore Co. LLC have accused Impax Laboratories Inc. of infringing two patents through its efforts to introduce a generic version of cholesterol drug Vytorin.

The plaintiffs, both owned by by Merck & Co. Inc., lodged the suit Thursday in the U.S. District Court for the District of New Jersey in response to Impax's filing of an abbreviated new drug application with the the U.S. Food and Drug Administration.

The ANDA seeks approval to market and sell a generic version of Vytorin before...
To view the full article, register now.